Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
BioDlink International Co., Ltd. operates as a clinical-stage biopharmaceutical firm, dedicating its resources to the development and future commercialization of novel oncology drugs and therapeutic solutions. Its pipeline features several key product candidates, including TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009, and its primary base of operations is situated in Suzhou, China.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EB
Target Price
The average target price of 1875.HK is 4.44 and suggests 26.5% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i